Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$26.6 million.

  • Fate Therapeutics' Free Cash Flow rose 1115.53% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.4 million, marking a year-over-year increase of 1290.1%. This contributed to the annual value of -$123.6 million for FY2024, which is 1070.11% up from last year.
  • Fate Therapeutics' Free Cash Flow amounted to -$26.6 million in Q3 2025, which was up 1115.53% from -$25.9 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Free Cash Flow registered a high of -$25.9 million during Q2 2025, and its lowest value of -$88.7 million during Q4 2021.
  • For the 5-year period, Fate Therapeutics' Free Cash Flow averaged around -$44.6 million, with its median value being -$35.0 million (2025).
  • Per our database at Business Quant, Fate Therapeutics' Free Cash Flow plummeted by 28656.26% in 2021 and then soared by 5706.92% in 2023.
  • Over the past 5 years, Fate Therapeutics' Free Cash Flow (Quarter) stood at -$88.7 million in 2021, then grew by 7.44% to -$82.1 million in 2022, then soared by 55.14% to -$36.8 million in 2023, then grew by 24.23% to -$27.9 million in 2024, then rose by 4.73% to -$26.6 million in 2025.
  • Its last three reported values are -$26.6 million in Q3 2025, -$25.9 million for Q2 2025, and -$35.0 million during Q1 2025.